Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept plus dexamethasone intravitreal implant for macular edema due to retinal vein occlusion
ChiCTR2100046387Phase 4Recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in retinal vein occlusion related macular edema (ME-RVO), branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) comparing Conbercept + dexamethasone implant with Conbercept monotherapy (2 arms). Primary endpoints: Retreatment time, Visual acuity and 3 more. Started Jun 2021; status: recruiting.
02
Drugs
conberceptdexamethasone
03
Conditions
retinal vein occlusion related macular edema (ME-RVO)branch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ChiCTR2100046387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046387.